Not Yet RecruitingNot Applicable

Serum FSH Levels During Controlled Ovarian Stimulation

Canada500 participantsStarted 2026-02-16

Plain-language summary

Follicle-stimulating hormone (FSH) plays a central role in controlled ovarian stimulation (COS) during in vitro fertilization (IVF) cycles. While baseline FSH is commonly used to assess ovarian reserve, the clinical significance of dynamic FSH changes during stimulation remains unclear. Limited evidence suggests that serum FSH levels during COS may reflect ovarian response and could be associated with follicular development and treatment outcomes, yet FSH is not routinely monitored throughout stimulation protocols. This prospective single-center cohort study aims to evaluate the dynamics of serum FSH levels during COS and to examine their association with ovarian response and IVF outcomes. Serum FSH, luteinizing hormone (LH) and estradiol (E2) will be measured at predefined time points during stimulation. Associations between FSH levels and oocyte yield, embryo development, and pregnancy outcomes will be analyzed to better understand the clinical relevance of FSH monitoring during IVF treatment.

Who can participate

Age range

18 Years – 44 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients undergoing controlled ovarian stimulation * All stimulation protocols (agonist and antagonist). * All gonadotropin formulation (Gonal-F, Menopur, Rekovelle, Puregon). Exclusion Criteria: * Cancer fertility preservation patients . * Patients over age 44.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

-Trigger day FSH levels

Timeframe: 60 months

Trigger day E2 levels

Timeframe: 60 months

Number of patients reaching trigger

Timeframe: 60 months

Number of oocytes retrieved

Timeframe: 60 months

Number of transferable embryos

Timeframe: 60 months

Trial details

NCT IDNCT07460674

SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-12

View on ClinicalTrials.gov More Female Subjects Undergoing Controlled Ovarian Hyperstimulation trials

Plain-language summary

Who can participate

Age range

18 Years – 44 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.